Upcoming Investor Conferences Featuring Xeris Biopharma
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a dynamic biopharmaceutical company that strives to enhance the quality of life for patients by bringing innovative therapies to market. This commitment will be highlighted as members of their management team participate in several key investor conferences in the near future.
Events on the Horizon
Investor interest is set to peak as Xeris confirms its attendance at notable conferences. The following events will showcase the company’s latest advancements:
- Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual): Xeris will engage in one-on-one meetings, alongside a fireside chat scheduled for February 12, 2025, at 1:20 PM ET.
- Leerink Global Healthcare Conference, in Miami: Attendees can catch Xeris at 1x1 meetings and a fireside chat on March 10, 2025, starting at 8:40 AM ET.
- Barclays 27th Annual Global Healthcare Conference, also in Miami: On March 11, 2025, Xeris will participate strictly in one-on-one meetings.
For personalized engagement, interested parties are encouraged to connect with each conference organizer to set up one-on-one discussions with Xeris executives.
Access to Webcasts and Presentations
Webcast details for each fireside chat will be disclosed through the Xeris investor relations page, ensuring that stakeholders can stay informed about the latest company insights and future strategies.
About Xeris Biopharma
Xeris (NASDAQ: XERS) is dedicated to improving patient outcomes through the development of pioneering biopharmaceutical products across diverse therapeutic areas. Their portfolio includes three FDA-approved products, enhancing treatment options for various health conditions:
- Recorlev: This therapy addresses endogenous Cushing’s syndrome.
- Gvoke: A ready-to-use glucagon solution for treating severe hypoglycemia.
- Keveyis: An established treatment for primary periodic paralysis.
Beyond these offerings, Xeris is advancing multiple development programs spearheaded by XP-8121, a subcutaneous injection for hypothyroidism, with potential for broad application in patient care. Utilizing its proprietary platforms, XeriSol and XeriJect, Xeris also collaborates on innovative therapies tailored for its partners.
Future Directions and Innovation
The driving force behind Xeris's growth is their unwavering focus on innovation in biopharmaceuticals, ensuring they meet the evolving needs of patients and the healthcare ecosystem. Their strategic engagement in leading conferences marks a significant step in strengthening relationships with investors, while also outlining their commitment to transparency and accountability.
Frequently Asked Questions
What is Xeris Biopharma known for?
Xeris Biopharma is known for developing and commercializing innovative biopharmaceutical products aimed at improving patient outcomes across various therapies.
When will Xeris participate in investor conferences?
Xeris is scheduled to participate in multiple investor conferences, including those organized by Oppenheimer, Leerink, and Barclays, throughout 2025.
What products does Xeris offer?
Xeris offers three commercially available products: Recorlev, Gvoke, and Keveyis, aimed at treating conditions like Cushing’s syndrome and severe hypoglycemia.
How can investors engage with Xeris at the conferences?
Investors can arrange one-on-one meetings through the respective conference sponsors to engage with Xeris management during the conferences.
Where can I find more information about Xeris?
More information about Xeris can be found on their official website or their investor relations page, providing updates on conference participation and product developments.
